THERANUM
The computed 12-month bankruptcy probability of THERANUM is 3.7% (moderate). The 2025 annual accounts show negative equity (€-22k) and a net result of €-27k. The company has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €-22k |
| Net result | €-27k |
| Active | 2 yrs |
| Locations | 1 |
Mixed profile: strong on profitability, weaker on health.
Computed on 4 of 5 axes. Not measured: growth. An unmeasured axis is not a zero: no data was read for it.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.
See plans →| Fiscal year | 2025 |
|---|---|
| Deposit | micro |
| Revenue | - |
| EBITDA | - |
| Net profit | €-27k |
| Cash flow | - |
| Staff costs | - |
| Income taxes | - |
| Dividends | - |
| Total assets | €23k |
| Equity | €-22k |
| Debt | €44k |
| of which ≤ 1y | €44k |
| of which > 1y | - |
| Working capital | €-22k |
| Employees (FTE) | - |
| 2025 | |
|---|---|
| Current ratio | 0.51 |
| Quick ratio | 0.51 |
| Working capital ratio | -94.8% |
| Solvency | -94.8% |
| Debt / equity | -2.06 |
| Long-term debt ratio | - |
| Interest coverage | - |
| Gross margin | - |
| Net margin | - |
| ROA | -116.8% |
| ROE | 123.2% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | 646d |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €23k |
| Formation expenses | 20 | €0 |
| Current assets | 29/58 | €23k |
| Amounts receivable within one year | 40/41 | €3k |
| Cash & bank | 54/58 | €20k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €23k |
| Equity | 10/15 | €-22k |
| Contributions / capital | 10/11 | €5k |
| Accumulated profits (losses) | 14 | €-27k |
| Amounts payable | 17/49 | €44k |
| Amounts payable within one year | 42/48 | €44k |
| Trade debts payable within one year | 44 | €44k |
| Income statement | ||
| Gross operating margin | 9900 | €-25k |
| Operating result | 9901 | €-26k |
| Financial charges | 65 | €323 |
| Result before taxes | 9903 | €-27k |
| Net result for the period | 9904 | €-27k |
| Result to be appropriated | 9905 | €-27k |
| NACE primary | Vervaardiging van farmaceutische grondstoffen(21100) |
| Legal form | Private limited company(610) |
| Incorporation | 27-02-2024 |
| Status | Active |
| Postal code | 4031 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62002C0832/00_000 | Wallonia | 927 m² | 1 · 246 m² | 13.9 m · 4 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
04-11-2024 Restructuring of share classes
Technical details
{
"events": [
{
"kind": "share_class_conversion",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": 10000000,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Jean-Michel GAUTHY",
"firm_city": null,
"firm_name": "GAUTHY, JACQUES \u0026 ROLANS \u2013 Soci\u00E9t\u00E9 Notariale",
"office_city": "Herstal",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2024-11-04",
"filing_date": "2024-10-30",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2024-10-29",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": "2024-10-29"
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "1006.498.130",
"name_full": "THERANUM",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"exp\u00E9dition de l\u2019assembl\u00E9e comportant deux procurations",
"la coordination des statuts"
],
"shareholders_after": [],
"share_classes_after": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | THERANUM |